Resultats globals: 4 registres trobats en 0.02 segons.
Articles, 4 registres trobats
Articles 4 registres trobats  
1.
7 p, 434.6 KB SCOT : a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer / Robles-Zurita, José (University of Glasgow. Institute of Health and Wellbeing) ; Boyd, Kathleen A. (University of Glasgow. Institute of Health and Wellbeing) ; Briggs, Andrew H. (University of Glasgow. Institute of Health and Wellbeing) ; Iveson, Timothy (Southampton University Hospital NHS Foundation Trust) ; Kerr, Rachel S. (University of Oxford. Department of Oncology) ; Saunders, Mark P. (The Christie Hospital) ; Cassidy, Jim (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Hollander, Niels Henrik (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Segelov, Eva (Australasian Gastro-Intestinal Trials Group (AGITG) and Monash University and Monash Health) ; Glimelius, Bengt (University of Uppsala) ; Harkin, Andrea (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Allan, Karen (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; McQueen, John (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences) ; Pearson, Sarah (University of Oxford. Department of Oncology, OCTO) ; Waterston, Ashita (Beatson West of Scotland Cancer Centre) ; Medley, Louise (Royal United Hospital) ; Wilson, Charles (Addenbrookes Hospital) ; Ellis, Richard (Royal Cornwall Hospitals NHS Trust) ; Essapen, Sharadah (St Luke's Cancer Centre, Royal Surrey County Hospital NHS Foundation Trust) ; Dhadda, Amandeep S. (Castle Hill Hospital) ; Hughes, Rob (Mount Vernon Cancer Centre) ; Falk, Stephen (Bristol Cancer Institute, Bristol, UK) ; Raouf, Sherif (Barking Havering and Redbridge University Hospital NHS Trust, Barking, UK) ; Rees, Charlotte (Southampton University Hospital NHS Foundation Trust) ; Olesen, Rene K (Zealand University Hospital, Department of Oncology and Palliative Care, Rǻdmandsengen 5) ; Propper, David (Queen Mary, University of London. Barts Cancer Institute) ; Bridgewater, John (University College London) ; Azzabi, Ashraf (Newcastle upon Tyne Hospitals NHS Foundation Trust) ; Farrugia, David (Gloucestershire Oncology Centre, Cheltenham General Hospital) ; Webb, Andrew (Brighton and Sussex University Hospital Trust) ; Cunningham, David (Royal Marsden (funded by NIHR BRC at the Royal Marsden)) ; Hickish, Tamas (Poole Hospital/Bournemouth University) ; Weaver, Andrew (Churchill Hospital, Oxford University Hospitals Foundation Trust) ; Gollins, Simon (North Wales Cancer Treatment Centre, Rhyl, UK) ; Wasan, Harpreet S (Hammersmith Hospital, Imperial College London) ; Paul, James (University of Glasgow. Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences)
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer. [...]
2018 - 10.1038/s41416-018-0319-z
British Journal of Cancer, Vol. 119 (november 2018) , p. 1332-1338  
2.
8 p, 196.5 KB Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer / Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ; Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ; Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ; Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485  
3.
7 p, 814.0 KB Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial / Siena, Salvatore (Università degli Studi di Milano (Italy)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Bodoky, Gyorgy (Szent László Hospital (Hungary)) ; Cunningham, David (Royal Marsden National Health Service Foundation Trust (United Kingdom)) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander)) ; Ruff, Paul (University of the Witwatersrand (South Africa)) ; Canon, Jean Luc (Grand Hôpital de Charleroi. Service d'Oncologie-Hématologie (Belgium)) ; Koukakis, Reija (Amgen Ltd. Department of Biostatistics (United Kingdom)) ; Demonty, Gaston (Amgen GmbH. Medical Development (Suïssa)) ; Hechmati, Guy (Amgen GmbH. Global Health Economics (Suïssa)) ; Douillard, Jean-Yves (Institut de Cancérologie de l'Ouest (France)) ; Universitat Autònoma de Barcelona
Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. [...]
2016 - 10.1136/esmoopen-2016-000041
ESMO Open, Vol. 1, Issue 2 (March 2016) , art. e000041  
4.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, F. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, I. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, A. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, J. C. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, C. (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, A. (Universidad de Valencia. Departamento de Hematología y Oncología Médica) ; Begum, R. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Gonzalez De Castro, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, S. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Z. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, A. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, G. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, N. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  

Vegeu també: autors amb noms similars
4 Cunningham, David
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.